Pegaspargase is a polyethylene glycol-conjugated asparaginase enzyme classified as an antineoplastic agent primarily used in the treatment of acute lymphoblastic leukemia. By depleting the essential amino… Read more
Pegaspargase is a polyethylene glycol-conjugated asparaginase enzyme classified as an antineoplastic agent primarily used in the treatment of acute lymphoblastic leukemia. By depleting the essential amino acids required for tumor cell growth, this therapeutic protein effectively inhibits the proliferation of malignant cells. This category includes high-quality reference standards, such as the active pharmaceutical ingredient, alongside related impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these materials for rigorous impurity profiling, method validation, and ongoing quality control of Pegaspargase formulations. Incorporating these analytical standards ensures precise identification and quantification of components throughout the manufacturing and testing lifecycle, supporting compliance with regulatory requirements and maintaining consistency in the characterization of this complex biological drug.